home / stock / cytk / cytk articles

CYTK Articles, Cytokinetics Incorporated - From 05/22/24

Stock Information
Company Name: Cytokinetics Incorporated
Stock Symbol: CYTK
Market: NASDAQ
Website: cytokinetics.com
Menu
CYTK CYTK Quote CYTK Short CYTK News CYTK Articles CYTK Message Board
Get CYTK Alerts

News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Announces Proposed Public Offering of Common Stock | Benzinga

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced plans to offer, subject t...
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology | Benzinga

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) announced that the Company will host the ...

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024 | Benzinga

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced five presentations relat...

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine | Benzinga

Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consis...
Omega Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates | Benzinga

Omega Therapeutics, Inc. (NASDAQ: OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. T...

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress | Benzinga

SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will host an investo...

Cytokinetics to Announce First Quarter Results on May 8, 2024 | Benzinga

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to...
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress | Benzinga

Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional...

$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today | Benzinga

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 5 years by 40.29% on an annualized basis producing an average annual return of...

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session | Benzinga

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced four presentations at t...
Previous 10 Next 10